Eloxx Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
Eloxx Pharmaceuticals has a total shareholder equity of $-20.0M and total debt of $18.4M, which brings its debt-to-equity ratio to -91.8%. Its total assets and total liabilities are $6.0M and $26.1M respectively.
Key information
-91.8%
Debt to equity ratio
US$18.41m
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.78m |
| Equity | -US$20.05m |
| Total liabilities | US$26.09m |
| Total assets | US$6.04m |
Recent financial health updates
Recent updates
Eloxx says lead asset failed in mid-stage cystic fibrosis trial
Sep 14Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line
Aug 15Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?
Sep 09
Eloxx Pharmaceuticals EPS misses by $0.06
May 06What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?
Feb 17Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis
Jan 13Financial Position Analysis
Short Term Liabilities: ELOX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ELOX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ELOX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ELOX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ELOX has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ELOX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.